GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2008

BioMS Obtains $10M Milestone Fee from Eli Lilly

  • BioMS Medical received $10 million from Eli Lilly as a result of positive initial Phase II/III data from dirucotide (MBP8298) in secondary progressive multiple sclerosis. Interim analysis covered efficacy and safety data from the first 200 patients to complete the trial.

    BioMS obtained $87 million upfront in exchange for giving Eli Lilly worldwide, exclusive rights to MBP8298. The deal, which was inked in December 2007, calls for $400 million more in development and sales milestone fees.

    While the terms of the milestone payments are not being disclosed, a majority are linked to success in development, according to Amanda Spadel, investor relations manager for BioMS. In addition to the sales-based milestones, BioMS is also eligible for escalating royalties.

    Results from the ongoing Phase II/III MAESTRO-01 trial are expected in the second half of 2009. Lilly could decide at this point to take over the fiscal responsibility for further development.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?